A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.
Overview
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations is a phase 1/2 interventional study registered as NCT06644768 by Daiichi Sankyo, with 137 participants planned, started 2024-10-30 and due to reach its primary completion in 2028-03-30. Interventions recorded: valemetostat tosylate, pembrolizumab. Conditions listed: Non-small Cell Lung Cancer, Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab
Shares Daiichi Sankyo, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Shares Daiichi Sankyo, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialHERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Shares Daiichi Sankyo, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Shares Daiichi Sankyo, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialIfinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Shares Daiichi Sankyo, Small-cell lung cancer.
- TrialSafety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Shares Daiichi Sankyo, Pembrolizumab, Small-cell lung cancer.
- TrialA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Shares Daiichi Sankyo, Small-cell lung cancer.
- TrialA Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
Shares Daiichi Sankyo, Non-small-cell lung cancer.